Therefore, over the past 20 years, treatment of RCC has evolved from immune cytokines (such as IL-2 and IFN-α) to tyrosine kinase inhibitors (TKI) targeting vascular endothelial growth factor receptor (VEGF), mTOR, or ALK. Here, MTOR is linked to renal cell carcinoma.